A major safety alert has put popular weight-loss and diabetes medicines under the scanner. The US Food and Drug Administration (FDA) has directed manufacturers of GLP-1 receptor agonist medicines to update their product labels with a warning about a potential increased risk of a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). Often described as an “eye stroke”, NAION occurs when blood flow to the optic nerve is reduced. It can cause sudden, painless vision loss in one eye and, in some cases, permanent impairment.The warning covers medicines including Ozempic and Wegovy (semaglutide), as well as other GLP-1 medicines such as liraglutide and tirzepatide. The FDA's review of 126 clinical trials found 6.4 NAION cases per 100,000 person-years among GLP-1 users, compared with 3.8 among those receiving comparator treatments. The agency describes the risk as rare but potentially serious. Importantly, the evidence does not establish that these medicines directly cause NAION, and the FDA has not advised all users to stop treatment. Mobile App - https://onelink.to/desc-youtube